ArticleScientific reports2026
Real-time quantification during indocyanine green fluorescent-guided surgery in canine soft tissue sarcomas and mast cell tumors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this pilot study was to evaluate the feasibility and utility of real-time tumor fluorescence-guided surgery (TFGS) with near-infrared fluorescence indocyanine green (NIRF-ICG) for the removal of spontaneous soft tissue sarcoma (STS) and mast cell tumor (MCT) at first presentation or recurrence in dogs. A dose of 0.5 mg/kg of ICG was administered 24 h before surgery, with a tumor-to-background (TBR) and signal-to-background ratio (SBR) cut-off of 2. Twenty-four dogs with 28 tumors (14 MCTs and 14 STSs) were included. TFGS was feasible in all STSs and in 11/14 MCTs. The median TBR of STS and MCT was 13 (IQR 26–9.4) and 5.8 (IQR 19–3.6) respectively. Considering the residual fluorescence in the wound bed and the histopathological results the sensitivity and specificity of NIRF-ICG excision were 80% and 78% in STS and 60% and 50% in MCT, respectively. Overall, resection was extended during TFGS in 64% of STSs and 55% of MCTs. These results convey the feasibility of TFGS with NIRF-ICG in canine STS surgical extirpation. However, the findings indicate more limited performance in MCT. The different performance in STS and MCT needs to be investigated in a larger population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.